Psoriatic Arthritis with Polyarthritis (≥5 Swollen Joints): What to Do After JAK Inhibitor Failure

Clinical scenario

This protocol applies to patients with peripheral psoriatic arthritis presenting as polyarthritis with five or more swollen joints, or as monoarthritis/oligoarthritis accompanied by poor prognostic factors — including structural damage, elevated acute phase reactants, dactylitis, or nail involvement.

Previous treatment — target not reached

The previous step used a JAK inhibitor (tofacitinib or upadacitinib). The treatment targets — improvement at 3 months, and remission or low disease activity at 6 months — were not achieved. This protocol defines the recommended next step.

Treatment approach (partial)

When a JAK inhibitor has produced an inadequate response or is not tolerated, switching to another biologic DMARD or JAK inhibitor — including a switch within the same therapeutic class — is the recommended next step.

The full regimen, sequencing, and individual agent selection are in the complete protocol →

Treatment targets

Improvement at 3 months Remission or low disease activity at 6 months

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2024-225531

In patients with polyarthritis, or those with monoarthritis/oligoarthritis and poor prognostic factors (eg, structural damage, elevated acute phase reactants, dactylitis or nail involvement), a csDMARD should be initiated rapidly, with methotrexate preferred in those with clinically relevant skin involvement.

In patients with an inadequate response or intolerance to a bDMARD or a JAKi, switching to another bDMARD or JAKi should be considered, including one switch within a class.

Treatment should be aimed at reaching the target of remission or, alternatively, low disease activity, by regular disease activity assessment and appropriate adjustment of therapy.

View source ↗